Skip to main content

Table 1 Frequency and characteristics of baseline tophi for patients in the randomized trials

From: Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Characteristics Pegloticase biweekly Pegloticase monthly Placebo
(n= 85) (n= 84) (n= 43)
Patients with one or more baseline tophi, n (%) 62 (73) 64 (76) 29 (67)
Total number of measurable baseline tophi 159 142 83
Median target area of measurable target tophi, mm2 (range) 378 (25 to 4,080) 377 (25 to 10,625) 460 (30 to 6,230)